New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
16:20 EDTORCL, SHPG, ABBV, FLML, DRI, NGLS, ETE, TRGPOn The Fly: Closing Wrap
Stocks on Wall Street had a quiet open and remained that way throughout the session. The averages moved in a narrow range but drifted mostly in positive territory, allowing the Dow and S&P 500 to close the week at all-time highs. The Nasdaq also notched a gain, despite being weighed on by shares of Oracle (ORCL), which slid after reporting earnings below Wall Street estimates. ECONOMIC EVENTS: In the U.S., no major economic data was reported. COMPANY NEWS: Shares of enterprise software provider Oracle sunk $1.69, or 3.98%, to $40.82 after the company’s fourth quarter results trailed analysts’ consensus estimates. Citigroup downgraded Oracle to Neutral from Buy citing weak license growth and "relatively aggressive" Q1 targets following the company's Q4 results... Shire (SHPG) shares trading in New York rose $31.18, or 16.26%, to $222.89 after the company confirmed it rejected a takeover offer from AbbVie (ABBV). Abbvie, which has tried unsuccessfully three times to strike a deal to buy the Ireland-based drugmaker, is considering raising its offer for Shire a fourth time, according to Bloomberg, citing two people with knowledge of the matter. MAJOR MOVERS: Among the notable gainers was car retailer CarMax (KMX), which surged $7.47, or 16.5%, to $52.75 after the company reported first quarter results that beat expectations. Also higher were shares of Flamel Technologies (FLML), which rose $2.40, or 18.79%, to $15.17 after the FDA changed its drug shortage website and now lists Flamel's Bloxiverz as the "first and only" approved neostigmine. Analysts at Summer Street believe the change could be a "hugely significant" milestone for Flamel and may mean that the FDA could be taking action to remove unapproved neostigmines offered by other companies. Among the noteworthy losers was Targa Resources Partners (NGLS), which fell $11.44, or 14.03%, to $70.11 after announcing last night that its takeover talks with Energy Transfer Equity (ETE) ended without a deal and the stock was downgraded at Wunderlich following the news. Shares of Targa Resources Partners and its parent, Targa Resources (TRGP), had spiked late in yesterday's session after Bloomberg reported that Energy Transfer was near a deal to buy them. Also lower was restaurant operator Darden (DRI), which dropped $1.94, or 3.92%, to $47.58 after stating that same-store sales at its Olive Garden restaurants had declined 3.5% last quarter and reporting earnings that disappointed. INDEXES: The Dow rose 25.62, or 0.15%, to 16,947.08, the Nasdaq advanced 8.71, or 0.2%, to 4,368.04, and the S&P 500 gained 3.39, or 0.17%, to 1,962.87.
News For ORCL;SHPG;ABBV;FLML;DRI;NGLS;ETE;TRGP From The Last 14 Days
Check below for free stories on ORCL;SHPG;ABBV;FLML;DRI;NGLS;ETE;TRGP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 10, 2014
16:15 EDTORCLKEYW, Oracle collaborate on advanced security solutions
Subscribe for More Information
09:40 EDTABBV, SHPGAbbVie, Shire not holding talks at this point as deadline approaches, CNBC says
AbbVie (ABBV) and Shire (SHPG) are not holding talks at this point, according to CNBC's David Faber, citing sources. Shire confirmed two days ago that it has received AbbVie's latest, raised takeover offer and that its board will meet to consider the proposal.
07:20 EDTORCLIridium completes implementation of Oracle's management and billing solution
Subscribe for More Information
July 9, 2014
18:31 EDTSHPGShareholders urge Allergan to make large acquisition, FT reports
Subscribe for More Information
18:21 EDTSHPGAllergan CEO seeks sizeable acquisitions, WSJ reports
Subscribe for More Information
08:19 EDTSHPG, ABBVAbbVie offer may not bring Shire to negotiating table, says BMO Capital
Subscribe for More Information
07:38 EDTSHPG, ABBVShire still has leverage, can get one more raise from AbbVie, Reuters contends
The selloff in shares of Shire (SHPG) and AbbVie (ABBV) yesterday following the latter's increased takeover offer suggests the market now expects a strong rebuttal from Shire, but "one plausible response" is a gently worded rejection that signals that another raised bid would be enough to secure a deal without a hostile play, contended Reuters Breakingviews columnists Neil Unmack and Robert Cyran. Shire’s board still has some leverage and can "probably extract one more increase in return for their recommendation," the authors believe. Reference Link
06:40 EDTABBV, SHPGAbbVie required to retract comments in Shire takeover battle, Reuters says
AbbVie (ABBV) has been required to take back comments made by its CEO Richard Gonzalez regarding shareholder support for its offer for Shire (SHPG), according to Reuters, citing a statement from the U.S. drugmaker. British takeover rules say that a rival is not allowed to claim support for its bid unless it has this in writing from shareholders. Reference Link
July 8, 2014
16:23 EDTSHPG, ABBVOn The Fly: Closing Wrap
Subscribe for More Information
12:48 EDTSHPG, ABBVOn The Fly: Midday Wrap
Subscribe for More Information
11:05 EDTSHPGHigh option volume stocks:
Subscribe for More Information
10:34 EDTFLMLFlamel Technologies management to meet with Summer Street
Luncheon Meeting with SVP Lisi to be held in Boston on July 14 at 12 pm hosted by Summer Street.
09:15 EDTABBV, SHPGOn The Fly: Pre-market Movers
Subscribe for More Information
09:05 EDTDRIDarden announces new national restaurant remodel design
Subscribe for More Information
09:05 EDTABBV, SHPGShire says board will meet to consider AbbVie proposal
Shire (SHPG) notes the announcement by AbbVie (ABBV) of a revised conditional non-binding proposal for a cash and share offer for Shire, comprising GBP 22.44 in cash and 0.8568 AbbVie shares per Shire share. "Shire confirms that AbbVie did not make the revised proposal to Shire before the announcement. The Board of Shire will meet to consider the proposal and a further announcement will be made in due course. Shareholders are strongly advised to take no action in relation to the AbbVie proposal. There can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made. This statement is being made by Shire without the prior agreement or approval of AbbVie," Shire stated.
08:07 EDTSHPG, ABBVShire volatility expected to move on AbbVie increasing proposal
Shire (SHPG) volatility is expected to move on AbbVie (ABBV) announcing that it has increased its proposal to GBP 22.44 in cash and 0.8568 ordinary shares of new AbbVie for each Shire share. This new proposal is an approximately 11% increase from AbbVie's prior indicative proposal. Overall option implied volatility of 49 is above its 26-week average of 34 according to Track Data, suggesting large near term price movement.
07:55 EDTABBV, SHPGAbbVie increases proposal for Shire to GBP 51.15 per share
Subscribe for More Information
07:54 EDTSHPG, ABBVShire jumps 3% to $244 after AbbVie ups buyout offer for fourth time
07:53 EDTABBV, SHPGAbbVie raises offer for Shire to 51.15 pounds per share
07:07 EDTETEEnergy Transfer Equity removed from US Focus List at Credit Suisse
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use